Transforming growth factor-β and T-cell-mediated immunoregulation in the control of autoimmune diabetes

Immunological Reviews

Volumn 212, Issue , 2006, Pages 185-202

  You, Sylvaine ^a   Thieblemont, Nathalie ^a   Alyanakian, Marie Alexandra ^a   Bach, Jean François ^a   Chatenoud, Lucienne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Immunoregulation; Regulatory T cells; TGF ; Type 1 diabetes

Indexed keywords

TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; MICE; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33746330703     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2006.00410.x     Document Type: Review

References (151)

1. Rossini AA, Faustman D, Woda BA, Like AA, Szymanski I, Mordes JP. Lymphocyte transfusions prevent diabetes in the BioBreeding/Worcester rat. J Clin Invest 1984;74:39-46.
2. Rossini AA, Slavin S, Woda BA, Geisberg M, Like AA, Mordes JP. Total lymphoid irradiation prevents diabetes mellitus in the Bio-Breeding/Worcester (BB/W) rat. Diabetes 1984;33:543-547.
3. Greiner DL, Handler ES, Nakano K, Mordes JP, Rossini AA. Absence of the RT-6 T cell subset in diabetes-prone BB/W rats. J Immunol 1986;136:148-151.
4. Greiner DL, Mordes JP, Handler ES, Angelillo M, Nakamura N, Rossini AA. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med 1987;166:461-475.
5. Rossini AA, Mordes JP, Greiner DL, Nakano K, Appel MC, Handler ES. Spleen cell transfusion in the Bio-Breeding/Worcester rat. Prevention of diabetes, major histocompatibility complex restriction, and long-term persistence of transfused cells. J Clin Invest 1986;77:1399-1401.
6. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1980;29:1-13.
7. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994;15:516-542.
8. Dardenne M, Lepault F, Bendelac A, Bach JF. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 1989;19:889-895.
9. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988;18:481-484.
10. Yasunami R, Debray-sachs M, Bach JF. Ontogeny of regulatory and effector T cells in autoimmune NOD mice. In: Shafrir E, ed. Frontiers in Diabetes Research. Lessons from animal diabetes III. London: Smith-Gordon, 1990:88-93.
11. Charlton B, Bacelj A, Slattery RM, Mandel TE. Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 1989;38:441-447.
12. Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 1975;141:697-702.
13. Minagawa H, Takenaka A, Itoyama Y, Mori R. Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J Neurol Sci 1987;78:225-235.
14. Miyazaki C, Nakamura T, Kaneko K, Mori R, Shibasaki H. Reinduction of experimental allergic encephalomyelitis in convalescent Lewis rats with cyclophosphamide. J Neurol Sci 1985;67:277-284.
15. Mahiou J, Walter U, Lepault F, Godeau F, Bach JF, Chatenoud L. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J Autoimmun 2001;16:431-440.
16. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989;169:1669-1680.
17. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986;35:855-860.
18. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J Exp Med 1987;166:823-832.
19. Herbelin A, Gombert JM, Lepault F, Bach JF, Chatenoud L. Mature mainstream TCR alpha beta(+)CD4(+) thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 1998;161:2620-2628.
20. Sempe P, Richard MF, Bach JF, Boitard C. Evidence of CD4+ regulatory T cells in the non-obese diabetic male mouse. Diabetologia 1994;37:337-343.
21. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969;166:753-755.
22. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell sub-population. J Exp Med 1996;184:387-396.
23. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
24. Lepault F, Gagnerault MC, Faveeuw C, Bazin H, Boitard C. Lack of L-selectin expression by cells transferring diabetes in NOD mice: insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatment. Eur J Immunol 1995;25:1502-1507.
25. You S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005;54:1415-1422.
26. Lepault F, Gagnerault MC. Characterization of peripheral regulatory CD4(+) T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000;164:240-247.
27. You S, Slehoffer G, Barriot S, Bach JF, Chatenoud L. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 2004;101(Suppl):14580-14585.
28. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity 1997;7:873-883.
29. Kurrer MO, Pakala SV, Hanson HL, Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:213-218.
30. Saoudi A, Seddon B, Fowell D, Mason D. The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med 1996;184:2393-2398.
31. Seddon B, Saoudi A, Nicholson M, Mason D. CD4+CD8- thymocytes that express L-selectin protect rats from diabetes upon adoptive transfer. Eur J Immunol 1996;26:2702-2708.
32. Friedline RH, Wong CP, Steeber DA, Tedder TF, Tisch R. L-selectin is not required for T cell-mediated autoimmune diabetes. J Immunol 2002;168:2659-2666.
33. Alyanakian MA, et al. Diversity of regulatory CD4+T cells controlling distinct organspecific autoimmune diseases. Proc Natl Acad Sci USA 2003;100:15806-15811.
34. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-1471.
35. Powrie F, Correa-oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
36. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001;194:629-644.
37. Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
38. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183-190.
39. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
40. Mccullagh P. The significance of immune suppression in normal self tolerance. Immunol Rev 1996;149:127-153.
41. Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med 1999;189:877-882.
42. Taguchi O, Kontani K, Ikeda H, Kezuka T, Takeuchi M, Takahashi T. Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens. Immunology 1994;82:365-369.
43. Taguchi O, Nishizuka Y. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J Exp Med 1987;165:146-156.
44. Salomon B, et al. B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440.
45. Lenschow DJ, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-293.
46. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells - they're back and critical for regulation of autoimmunity! Immunol Rev 2001;182:149-163.
47. Tisch R, Wang B, Atkinson MA, Serreze DV, Friedline R. A glutamic acid decarboxylase 65-specific Th2 cell done immunoregulates autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;166:6925-6936.
48. You S, Chen C, Lee WH, Brusko T, Atkinson M and Liu CP. Presence of diabetes-inhibiting, glutamic acid decarboxylase-specific, IL-10-dependent, regulatory T cells in naive nonobese diabetic mice. J Immunol 2004;173:6777-6785.
49. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993;74:1089-1100.
50. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002;169:2461-2465.
51. Mosmann TR, Coffman RL. TH1 and TH2 eels: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
52. Bach JF and Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001;19:131-161.
53. Elias D, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997;46:758-764.
54. Tian J, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183:1561-1567.
55. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999;163:1178-1187.
56. Rapoport MJ, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99.
57. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996;184:1093-1099.
58. Balasa B, Van Gunst K, Jung N, Katz JD, Sarvetnick N. IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. Cell Immunol 2000;202:97-102.
59. Wang B, Gonzalez A, Hoglund P, Katz JD, Benoist C, Mathis D. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998;47:1207-1211.
60. Castro AG, et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 2000;192:1529-1534.
61. Phillips JM, Parish NM, Drage M, Cooke A. Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes. J Immunol 2001;167:6087-6091.
62. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992;89:421-425.
63. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995;147:1193-1199.
64. King C, et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998;8:601-613.
65. Moritani M, et al. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta 1. J Clin Invest 1998;102:499-506.
66. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003;100:10878-10883.
67. Han HS, Jun HS, Utsugi T, Yoon JW. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice. J Autoimmun 1997;10:299-307.
68. Zekzer D, et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 1997;46:1124-1132.
69. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1 -mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996;183:2669-2674.
70. Bridoux F, et al. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J Exp Med 1997;185:1769-1775.
71. Seddon B, Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. J Exp Med 1999;189:279-288.
72. Levings MK, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002;196:1335-1346.
73. Piccirillo CA, et al. CD4(+)CD25(+) Regulatory T Cells Can Mediate Suppressor Function in the Absence of Transforming Growth Factor beta1 Production and Responsiveness. J Exp Med 2002;196:237-246.
74. Gregori S, Giarratana N, Smiroldo S and Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003;171:4040-4047.
75. Blanchard D, Bach MA. Thymic function in NZB mice. III. Impairment of the activity of specific suppressor cells involved in the regulation of antibody production against sheep red blood cells. Clin Exp Immunol 1980;42:1-9.
76. Chiang YJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000;403:216-220.
77. Wohlfert EA, Callahan MK, Clark RB. Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol 2004;173:1059-1065.
78. Dresser DW. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962;5:378-388.
79. Dresser DW, Mitchison NA. The mechanism of immunological paralysis. Adv Immunol 1968;8:129-181.
80. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953;172:603-606.
81. Harrison LC, Dempseycollier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996;184:2167-2174.
82. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-10256.
83. Al-sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994;24:2104-2109.
84. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997;186:2039-2043.
85. Tian JD, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996;2:1348-1353.
86. Ellas D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994;343: 704-706.
87. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002;18(Suppl):S21-26.
88. Harrison LC, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004;27:2348-2355.
89. Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol 2005;26:608-612.
90. Chaillous L, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000;356:545-549.
91. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-1753.
92. Monaco AP, Wood ML, Russell PS. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann NY Acad Sci 1966;129:190-209.
93. Wood ML, Monaco AP, Gozzo JJ, Liegeois A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971;3:676-679.
94. Nicolls MR, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD 3-like monoclonal antibody. Transplantation 1993;55:459-468.
95. Plain KM, Chen J, Merten S, He XY, Hall BM. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 1999;67:605-613.
96. Darby CR, Morris PJ, Wood KJ. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells. Transplantation 1992;54:483-490.
97. Cobbold SP, Qin S, Leong LY, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992;129:165-201.
98. Waldmann H, Cobbold S. Regulating the immune response to transplants, a role for CD4+ regulatory cells? Immunity 2001;14:399-406.
99. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002;14:592-600.
100. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-328.
101. Adler SH, Turka LA. Immunotherapy as a means to induce transplantation tolerance. Curr Opin Immunol 2002;14:660-665.
102. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-1208.
103. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in non-obese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-127.
104. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3: 123-132.
105. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-2954.
106. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982;12:979-982.
107. Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 1992;89:3434-3438.
108. Kohm AP, et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005;174:4525-4534.
109. Alegre ML, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57:1537-1543.
110. Bolt S, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-411.
111. Herold KC, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698.
112. Herold KC, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769.
113. Keymeulen B, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608.
114. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-1364.
115. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003;198:1179-1188.
116. Nakamura K, et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004;172:834-842.
117. Bach JF, Francois Bach J. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189-198.
118. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-257.
119. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
120. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003;81:331-371.
121. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352.
122. Read S, Mahnstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
123. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-142.
124. Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21.
125. Wildin RS, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
126. Fu S, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4+ CD25- precursors. Am J Transplant 2004;4: 1614-1627.
127. Cobbold SP, et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004;172:6003-6010.
128. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol 1999;162:6368-6377.
129. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004;16:89-98.
130. Baecher-Allan C, Wolf E, Hafler DA. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells. Clin Immunol 2005;115:10-18.
131. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-341.
132. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-735.
133. Chen W, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
134. Park HB, Paik DJ, Jang E, Hong S, Youn J. Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. Int Immunol 2004;16:1203-1213.
135. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005;201:127-137.
136. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004;173:7259-7268.
137. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-5153.
138. Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004;172:923-928.
139. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002;51:3353-3361.
140. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-920.
141. Feillet H, Bach JF. On the mechanisms of the protective effect of infections on type 1 diabetes. Clin Dev Immunol 2004;11:191-194.
142. Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract 1990;8:85-89.
143. Bras A, Aguas AP. Diabetes-prone NOD mice are resistant to Mycobacterium avium and the infection prevents autoimmune disease. Immunology 1996;89:20-25.
144. Oldstone MB. Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence. J Exp Med 1990;171:2077-2089.
145. Takei I, et al. Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. J Autoimmun 1992;5:665-673.
146. Wilberz S, Partke HJ, Dagnaes-hansen F, Herberg L. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. Diabetologia 1991;34:2-5.
147. Cooke A, et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol 1999;21:169-176.
148. Alyanakian MA, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006;55:in press.
149. Shehadeh N, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994;343:706-707.
150. Schaad UB, Mutterlein R, Coffin H. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-bund, placebo-controlled multicenter study. Chest 2002;122:2042-2049.
151. Del-Rio-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcantara S, AvilaCastanon L, Gomez-Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr) 2003;31:7-13.